The Chronic Lymphocytic Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ERIC 2022 | The impact of complex karyotype on treatment efficacy and prognosis in CLL
Antonio Cuneo, MD, St. Anna University Hospital, Ferrara, Italy, explains the impact of complex karyotype on treatment efficacy in chronic lymphocytic leukemia (CLL). Whilst it has been shown that complex karyotype is associated with a poor response to chemoimmunotherapy, the impact of this marker in patients treated with BTK and Bcl-2 inhibitors remains unclear. This interview took place at the 2022 European Research Initiative on CLL (ERIC) Meeting.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
